Table 1 Function of human cancer MHC-I expression
From: Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Cancer type | MHC-I type | Number of patients | Analysis method | Function | Reference |
|---|---|---|---|---|---|
Muscle-invasive bladder cancer | Pan HLA-I (HLA-A, B, C) | 65 | Immunohistochemistry by anti-pan HLA-I antibody EMR 8 − 5 | Positive | [79] |
Pan HLA-I (HLA-A, B, C) | 30 | Immunohistochemistry by anti-pan HLA-I antibody EMR 8 − 5 | Positive | [84] | |
Non-small-cell lung cancer | B2M | / | Bioinformatic analysis | Positive | [85] |
Clear cell renal cell carcinoma | Pan HLA-I (HLA-A, B, C) | 45 | Immunohistochemistry by anti-pan HLA-I antibody EMR 8 − 5 | Positive | [80] |
Invasive breast cancer | Pan HLA-I (HLA-A, B, C) | 439 | Immunohistochemistry by anti-HLA-I heavy chain antibody HC10 | Negative | [86] |
B2M | 424 | Immunohistochemistry by polyclonal rabbit-anti-B2M antibody | Negative | [86] | |
Advanced gastric cancer | HLA-E | 232 | Immunohistochemistry by anti-HLA-E antibody MEM-E/02 | Negative | [90] |
Nasopharyngeal carcinoma | HLA-F | 74 | Immunohistochemistry by anti-HLA-F antibody EPR6803 | Negative | [93] |
Colorectal cancer | Pan HLA-I (HLA-A, B, C) | 97 | Immunohistochemistry by anti-pan HLA-I antibody EMR 8 − 5 | Positive | [81] |
Pan HLA-I (HLA-A, B, C) | 455 | Immunohistochemistry by anti-HLA-I heavy chain antibody HC10 | High expression and absent lead to a good prognosis, low expression leads to a poor prognosis | [88] | |
HLA-B/C | 2863 | Bioinformatic analysis through StataSE | Positive | [101] | |
HLA-A | 88 | Immunohistochemistry by anti-HLA-A antibody HCA2 | Negative | [102] | |
HLA-G | 157 | Immunohistochemistry by anti-HLA-G-PE antibody MEM-G/09 | Negative | [96] | |
HLA-G | 137 | Immunohistochemistry by anti-HLA-G antibody MEM-G/2 | Negative | [98] | |
HLA-E | 137 | Immunohistochemistry by anti-HLA-E antibody MEM-E/02 | Positive | [98] | |
HLA-G | 201 | Immunohistochemistry by anti-HLA-G antibody HGY | Negative | [99] | |
Endometrial cancer | Pan HLA-I (HLA-A, B, C) | 554 | Immunohistochemistry by anti-HLA-I heavy chain antibody HC10 | Positive | [103] |
Ovarian cancer | Co-expression of HLA-B/C and B2M | 232 | Immunohistochemistry by anti-HLA-I heavy chain antibody HC10 and polyclonal anti-B2M antibody | Positive | [104] |